Genometrix Withdraws Initial Public Offering; Plans to Seek Private Financing | GenomeWeb

NEW YORK, Feb 26 – Genometrix on Monday withdrew its application for an initial public offering, citing poor market conditions.

“The markets are so volatile, we decided not to proceed with it [the offering] at this time,” said Bobbie Ireland, senior manager of marketing communications at Genometrix of The Woodlands, Texas.

Ireland said the company, which filed for the IPO with the US Securities and Exchange Commission last March, has recently started working with banks in an effort to secure private financing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.